New York, NY -- (SBWIRE) -- 12/05/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: AT&T Inc (NYSE:T), Monster Worldwide, Inc (NYSE:MWW), Progenics Pharmaceuticals, Inc (NASDAQ:PGNX), RECKITT BENCKISER PL (OTCMKTS:RBGLY)
AT&T Inc (NYSE:T) showed a volume of 27.22 million shares by the end of last trade whereas the average volume of the stock remained 22.06 million shares. The stock opened the session at $34.34 but then moved to $34.60. At that price, the stock showed a negative performance of -0.40%. AT&T Inc. (AT&T) is a holding company. AT&T is a provider of telecommunications services in the United States and worldwide. Services offered include wireless communications, local exchange services and long-distance services. AT&T operates in four segments: Wireless, Wireline, Advertising Solutions and Other. Its Wireless subsidiaries provide both wireless voice and data communications services across the United States, and through roaming agreements, in a substantial number of foreign countries. Wireline subsidiaries provide primarily landline voice and data communication services,
Will AT&T Get Buyers Even After The Recent Rally? Find Out Here
Monster Worldwide, Inc (NYSE:MWW) opened the session at $5.41 and closed the session at $5.34. The stock showed a negative performance of -2.39% in previous trading session. Monster Worldwide, Inc. (Monster Worldwide) is parent company of Monster, the global online employment solution. With a presence in approximately 55 countries globally, including key markets in North America, Europe, South America and the Asia-Pacific region, Monster offers online recruiting solutions. Through online media sites and services, Monster Worldwide delivers audiences to advertisers. It operates in three segments: Careers-North America, Careers-International, and Internet Advertising & Fees.
Has MWW Found The Bottom And Ready To Gain Momentum? Find Out Here
Progenics Pharmaceuticals, Inc (NASDAQ:PGNX) opened the session at $4.71 and closed the session at $4.62. The stock showed a negative performance of -2.74% in previous trading session. The beta of the stock remained 1.23. Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers. In gastroenterology, its first commercial product is RELISTOR subcutaneous injection. Its principal product candidate is PSMA ADC,
Why Should Investors Buy PGNX After the Recent Fall? Just Go Here and Find Out
RECKITT BENCKISER PL (OTCMKTS:RBGLY) the stock advanced 0.38% and finished the session at $15.87. Traded with volume of 201,629.00 shares in the prior session and the average volume of the stock remained 100,191.00 shares. The beta of the stock remained 0.46.
Will RBGLY Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)